Global Value Access Strategy Director

Vertex Inc. • Boston, MA

1d • Hybrid

About The Position

Vertex operates at the forefront of scientific innovation and has successfully developed and commercialized multiple breakthrough medicines for Cystic Fibrosis (CF), Casgevy, a gene therapy for sickle cell disease and beta-thalassemia and Journavx, a novel new treatment for moderate to severe acute pain. Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases including programs in kidney diseases, Type 1 diabetes, among others. Vertex is investigating and advancing cell therapies aimed at treating an underlying cause of T1D — the absence of insulin-producing cells. For over 100 years, improvements in insulin and technologies for insulin management have helped people with T1D manage their condition. However, there are very few approved treatments that address a root cause of T1D — the absence of insulin-producing cells in the pancreatic islets. Our investigational approach is to replace the insulin-producing cells that have been destroyed in people with T1D. We’re evaluating multiple approaches to deliver our proprietary, fully-differentiated, insulin-producing cells. Market Access is a key commercial function that ensures transformative Vertex therapies are appropriately funded and ultimately make it into the hands of the patients around the world. GVAS works cross-functionally and across regions to ensure the payer view is represented in commercial and development plans across the lifecycle. We are driven by a desire to deliver groundbreaking pricing & reimbursement solutions to allow our medicines to reach patients faster than ever before. The Director, T1D will serve as a T1D Market Access Lead within our Cell and Gene Therapy (CGT) portfolio in the Global Value and Access Strategy (GVAS) team. The individual will be responsible for leading the development of Global Market Access strategies for early-stage pipeline assets in the T1D portfolio, ensuring enterprise planning to enable optimal patient access. In this capacity, the individual will help to inform development of T1D prioritization/portfolio strategy and ultimately the commercial strategy, to ensure price and access success. This individual will lead the assessment of price/access potential and key considerations such as indication/launch sequencing for these new indications in close collaboration with cross-functional and regional access colleagues. This role will also contribute to cross-portfolio capability building and thought leadership projects that advance knowledge of and readiness for the rapidly evolving Global payer environment. This position reports to the Senior Director, Cell and Gene Therapy within GVAS.

Requirements

• 8+ years of direct biotechnology / pharmaceutical industry experience and/or payer experience
• Deep working knowledge of both US and ex-US healthcare systems required, experience in comparable global and/or specialty disease area role considered a plus
• Demonstrated ability to think strategically and make sound pricing and market access recommendations
• Entrepreneurial, energetic, dynamic, enthusiastic, decisive, and self-motivated; possesses a sense of urgency with the ability and strong desire to "make things happen"
• Strong practical, quantitative and analytical skills combined with a sound understanding of how to successfully apply pricing & reimbursement / HEOR principles
• General experience in commercialization and drug development
• Demonstrated ability to effectively operate within highly cross-functional teams within a matrix environment
• Exhibits outstanding written and oral communication skills, including the ability to effectively write and deliver presentations to professionals at all levels within Vertex
• Demonstrated relationship building at all levels of the organization and across geographies
• Recognized as a team player with excellent interpersonal skills who is flexible and reliable
• Displays sound ethics and a fit for Vertex’s core values
• BA/BS in field of study requiring quantitative analysis; advanced degree preferred

Nice To Haves

• Cell and Gene Therapy experience preferred

Responsibilities

• Lead payer strategic planning to ensure value and access optimization for early-stage pipeline assets in the T1D portfolio
• Lead development and refinement of Market Access strategies and core Global P&R deliverables operating within the cross-functional, cross-regional commercialization process
• Accountable for Global Payer Plans, which integrate value evidence generation, strategic pricing, value communications, stakeholder engagement to support successful reimbursement and pricing
• Ensure the payer position is consistently represented to internal stakeholders and ensure robust strategic input into commercialization and development decisions
• Support strategies with deep functional knowledge, in-depth market research, environmental data & analogs
• Inform financial forecasts
• Partner with HEOR and Global Marketing to ensure robust value proposition and integrated evidence plans are optimized to support global market access and reimbursement
• Lead capability building and thought leadership projects that advance knowledge of and readiness for the rapidly evolving Global payer environment
• Maintain industry awareness and proactively address changes in market trends, competition, product acceptance and new product releases and adjust Market Access plans accordingly
• Collaborate closely with HEOR, International P&R, Corporate Affairs, US Managed Markets, Countries, Marketing and Clinical Development counterparts to ensure value and access optimization

Benefits

• From medical, dental and vision benefits to generous paid time off (including a week-long company shutdown in the Summer and the Winter), educational assistance programs including student loan repayment, a generous commuting subsidy, matching charitable donations, 401(k) and so much more.

What This Job Offers

• Job Type: Full-time
• Career Level: Director
• Number of Employees: 501-1,000 employees